RE: Trials/contracts6 May 2025 20:58
Progress is tangible, revenues will have increased and losses down ( see last update )
Plus now 3 new contracts, a JV with Weatherden, a3rd peer review and a regulatory environment that REQUIRES drug companies to use A.I, mathematical modelling etc .
Plus , some of lowest salaries on AIM
And of the £1.2mln cap , about £700k cash/cash equivalents